Tim Knotnerus (file photo)
AgomAb Therapeutics looks to take its 'true MET agonist' for broad use into the clinic with $74M round
Years ago, argenx reached out to Paolo Michieli, an Italian professor at the University of Torino. They wanted an expert’s help finding MET antagonists, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
